Dietary supplementation of n‐3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA‐cp rat

Hassanali, Z.; Ametaj, Burim N.; Field, Catherine J.; Proctor, Spencer D.; Vine, Donna F.

doi:10.1111/j.1463-1326.2009.01130.x

Cited by 63 publications

(58 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was in contrast, again, with Simão et al [30]. Our results are in line with what reported by Hassanali et al [47] in rats: acute dietary n-3 PUFA dietary supplementation can improve fasting as well as post-prandial lipid metabolism and components of the associated inflammatory response in the JCR/LA-cp rat.…”

Section: Discussioncontrasting

confidence: 54%

Effects of n‐3 PUFA on insulin resistance after an oral fat load

Derosa

Cicero

Fogari

et al. 2011

Euro J Lipid Sci & Tech

View full text Add to dashboard Cite

The aim of this study was to evaluate the effects of v-3 PUFA (n-3 PUFA) on lipid profile and insulin resistance biomarkers. Patients were assigned to receive placebo or n-3 PUFA 1 g three times a day, during the meals, for 6 months. We evaluated: body mass index (BMI), body weight, fasting plasma glucose (FPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), blood pressure, lipid profile, resistin (r), retinol binding protein-4 (RBP-4), adiponectin (ADN), visfatin, and vaspin. Furthermore patients underwent an oral fat load (OFL) and an euglycemic hyperinsulinemic clamp to evaluate M value, and total glucose requirement (TGR). Triglycerides value obtained with n-3 PUFA was lower, while HDL-C, and ADN values were higher compared to placebo. After the OFL, and comparing the OFL performed at the baseline and at the end of the study, there was a decrease of triglycerides (Tg), resistin (r), and RBP-4 values, and an increase of ADN value with n-3 PUFA, but not with placebo. We conclude that the treatment with n-3 PUFA resulted in a greater improvement of lipid profile and ADN compared to placebo in a baseline condition, and an improvement of all insulin resistance parameters after an OFL. Practical applications:The inverse association between dietary intake of n-3 PUFA and cardiovascular disease morbidity/mortality was primarily established following the observation that the Greenland Inuits had low mortality from coronary heart disease despite a fat-rich diet. Our group has already shown that n-3 PUFA improved the lipid profile and the coagulation, fibrinolytic, and inflammatory parameters compared to placebo. We also observed that highly purified n-3 PUFA supplementation significantly reduced the blood pressure, pulse pressure, and basal heart rate in hypertriglyceridemic patients with normal-high blood pressure. The current study showed that treatment with n-3 PUFA not only improved lipid profile in a baseline situation, but it also improved all insulin resistance parameters in a post-prandial situation simulated with an OFL. This is another important action of the n-3 PUFA which can increase their utility in the clinical practice.

show abstract

Section: Discussioncontrasting

confidence: 54%

Effects of n‐3 PUFA on insulin resistance after an oral fat load

Derosa

Cicero

Fogari

et al. 2011

Euro J Lipid Sci & Tech

View full text Add to dashboard Cite

show abstract

“…Our laboratory has previously reported that dietary fatty acid composition alters haptoglobin levels of the cp/cp male rat following an oral fat challenge (16). The reduction of postprandial plasma haptoglobin levels observed in rimonabant-treated rats (Fig.…”

Section: Rimonabant and Proinflammationmentioning

confidence: 88%

“…We conclude that rimonabant improves renal disease and intestinal lipid oversecretion associated with an animal model of the metabolic syndrome that appears to be independent of hyperinsulinemia or macrovascular dysfunction. metabolic syndrome; chylomicron overproduction; inflammation; microalbuminuria; glomerular sclerosis; plasminogen activator inhibitor-1; apolipoprotein B48 EXCESSIVE WEIGHT GAIN, PARTICULARLY in the form of abdominal (visceral) adipose tissue, is a major public health problem in prosperous societies worldwide (16,65). The resultant abdominal obesity has driven a developing epidemic of prediabetic insulin resistance and cluster of associated metabolic abnormalities that are termed the metabolic syndrome (9, 35).…”

mentioning

confidence: 99%

Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cprat model of prediabetic metabolic syndrome

Russell

Kelly

Diané

et al. 2010

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Vine DF, Proctor SD. Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. Am J Physiol Gastrointest Liver Physiol 299: G507-G516, 2010. First published May 27, 2010 doi:10.1152/ajpgi.00173.2010 is a specific antagonist of the cannabinoid-1 receptor. Activation of the receptor initiates multiple effects on central nervous system function, metabolism, and body weight. The hypothesis that rimonabant has protective effects against vascular disease associated with the metabolic syndrome was tested using JCR:LA-cp rats. JCR:LA-cp rats are obese if they are cp/cp, insulin resistant, and exhibit associated micro-and macrovascular disease with end-stage myocardial and renal disease. Treatment of obese rats with rimonabant (10 mg·kg Ϫ1 ·day Ϫ1 , 12-24 wk of age) caused transient reduction in food intake for 2 wk, without reduction in body weight. However, by 4 wk, there was a modest, sustained reduction in weight gain. Glycemic control improved marginally compared with controls, but at the expense of increased insulin concentration. In contrast, rimonabant normalized fasting plasma triglyceride and reduced plasma plasminogen activator inhibitor-1 and acute phase protein haptoglobin in cp/cp rats. Furthermore, these changes were accompanied by reduced postprandial intestinal lymphatic secretion of apolipoprotein B48, cholesterol, and haptoglobin. While macrovascular dysfunction and ischemic myocardial lesion frequency were unaffected by rimonabant treatment, both microalbuminuria and glomerular sclerosis were substantially reduced. In summary, rimonabant has a modest effect on body weight in freely eating obese rats and markedly reduces plasma triglyceride levels and microvascular disease, in part due to changes in intestinal metabolism, including lymphatic secretion of apolipoprotein B48 and haptoglobin. We conclude that rimonabant improves renal disease and intestinal lipid oversecretion associated with an animal model of the metabolic syndrome that appears to be independent of hyperinsulinemia or macrovascular dysfunction. metabolic syndrome; chylomicron overproduction; inflammation; microalbuminuria; glomerular sclerosis; plasminogen activator inhibitor-1; apolipoprotein B48 EXCESSIVE WEIGHT GAIN, PARTICULARLY in the form of abdominal (visceral) adipose tissue, is a major public health problem in prosperous societies worldwide (16,65). The resultant abdominal obesity has driven a developing epidemic of prediabetic insulin resistance and cluster of associated metabolic abnormalities that are termed the metabolic syndrome (9, 35). Insulin resistance leads to chronic hyperinsulinemia and has been implicated as a major determinant of early development of macro-and microvasculopathy, including atherosclerosis, ischemic cardiovascular disease (CVD), and renal damage, which are strongly associated with the metabolic syndrome (9, 26). The contribution of the metabolic syndrome to the development of cardiovascular and re...

show abstract

“…Simopoulos (2016) menyatakan bahwa omega 3 mampu menghalangi terbentuknya enzim lipogen yang berperan dalam pembentukan lemak yang akan terakumulasi pada sel adiposa. Penelitian yang dilakukan oleh Hassanali et al (2010) menjelaskan bahwa pemberian suplemen omega 3 mampu menurunkan berat badan pada kondisi hiperkolesterolemia, sejalan dengan penelitian yang dilakukan oleh Ruzickova et al (2004) dan Mendez-Sanchez et al (2001). Hasil analisis ANOVA menunjukkan bahwa tidak terdapat perbedaan yang signifikan antar perlakuan.…”

Section: Perubahan Bobot Tikusunclassified